Kala Pharmaceuticals Inc

NASDAQ:KALA   3:59:50 PM EDT
1.70
+0.08 (+4.63%)
Regulatory, Mergers / Acquisitions

Kala Pharmaceuticals Acquires Combangio For An Aggregate Value of About $16.1 Mln

Published: 11/15/2021 15:06 GMT
Kala Pharmaceuticals Inc (KALA) - Kala Pharmaceuticals Acquires Combangio, Expanding Its Pipeline With a Clinical-stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (pced) and Other Rare Ocular Surface Diseases.
Kala Pharmaceuticals Inc - Plans to Submit Ind Application to FDA and Initiate a Phase 2/3 Trial of Kpi-012 in Q3 of 2022.
Kala Pharmaceuticals Inc - Acquired Combangio for an Aggregate Value of About $16.1 Million.